Response to “Optimizing triptan safety in emergency settings under cardiovascular risk uncertainty”

Détails bibliographiques
Auteurs principaux:	Ido Peles, Gal Ifergane
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Headache: The Journal of Head and Face Pain
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Optimizing triptan safety in emergency settings under cardiovascular risk uncertainty
par: Yalcin Golcuk
Publié: (2025)

Cardiovascular risk and triptan usage among patients with migraine
par: Ido Peles, et autres
Publié: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
par: David Croteau, et autres
Publié: (2026)

The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis
par: Scott W. Kirkland, et autres
Publié: (2024)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
par: Keshet Pardo, et autres
Publié: (2025)

Incidence and outcome of sudden severe headache in the emergency department
par: Ane Skaare Sjulstad, et autres
Publié: (2025)

Association between wildfire smoke exposure and pediatric emergency department visits for headache
par: Hannah F. J. Shapiro, et autres
Publié: (2025)

Imaging and physiology across the high–low cerebrospinal fluid pressure spectrum: Navigating diagnostic uncertainty in headache practice
par: Andrew L. Callen, et autres
Publié: (2026)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
par: María Clara García‐Castillo, et autres
Publié: (2026)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
par: Rebecca Lindsay, et autres
Publié: (2024)

Driving evidence to practice for management of migraine in the emergency department: A systematic approach to guideline implementation
par: Jennifer Robblee, et autres
Publié: (2026)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
par: David Kudrow, et autres
Publié: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
par: Koichi Ikeda, et autres
Publié: (2025)

The safety and feasibility of transcranial direct current stimulation and exercise therapy for the treatment of cervicogenic headaches: A randomized pilot trial
par: Kaiden Jobin, et autres
Publié: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
par: Geneviève Tourigny‐Ruel, et autres
Publié: (2026)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
par: Serena Laura Orr, et autres
Publié: (2024)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
par: Christopher C. Anderson, et autres
Publié: (2024)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
par: Jennifer Robblee, et autres
Publié: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
par: Jennifer Robblee, et autres
Publié: (2024)

Genetically proxied liability to migraine and risk of intracranial aneurysm and subarachnoid hemorrhage
par: Iyas Daghlas, et autres
Publié: (2024)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
par: David W. Dodick, et autres
Publié: (2025)

Retrofitted adult interventions aren't good enough: Why children and adolescents deserve tailored evidence‐based care for migraine in the emergency department
par: Serena L. Orr
Publié: (2026)

From adolescence to adulthood: The role of dietary quality in headache and temporomandibular disorder risks
par: Daniela A. Godoi Gonçalves
Publié: (2025)

Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study
par: Seonyoung Kang, et autres
Publié: (2024)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
par: Chay Ngee Lim, et autres
Publié: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
par: Larry Charleston, et autres
Publié: (2026)

Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral pharmacotherapies
par: Jennifer Robblee, et autres
Publié: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
par: Shiri Shinan‐Altman, et autres
Publié: (2026)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
par: Dawn C. Buse, et autres
Publié: (2025)

Epidemiology of new daily persistent headache: A systematic review and meta‐analysis with comparison in regard to different age groups, sex, and patient sample settings
par: Maksymilian Osiowski, et autres
Publié: (2025)

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
par: Richard B. Lipton, et autres
Publié: (2024)

Response to: Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics
par: Christina Murphy, et autres
Publié: (2025)

Low pulse pressure and high serum complement C1q are risk factors for hemodialysis headache: A case–control study
par: Quan Gan, et autres
Publié: (2024)

Response to: Disagreement with Categorization of Clinical Trials included in Treadwell et al. Systematic Review and Meta‐Analysis
par: Jonathan R. Treadwell, et autres
Publié: (2025)

Is poor dietary quality in adolescence a risk factor for painful temporomandibular disorders and headaches in young adulthood? A prospective study in the Danish National Birth Cohort
par: Mojdeh Mansoori, et autres
Publié: (2025)

Higher artificial intelligence‐ ECG atrial fibrillation prediction model output and estimated physiologic aging predict higher risk of adverse vascular events in patients with migraine
par: Ping‐Hao Yang, et autres
Publié: (2026)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
par: Janosch Fox, et autres
Publié: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
par: Alicia Alpuente, et autres
Publié: (2026)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
par: Ann I. Scher, et autres
Publié: (2024)

Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
par: Michael L. Garelja, et autres
Publié: (2026)

Documents similaires

Documents similaires